AU2004315596B2 - Inhibitors of cellular necrosis - Google Patents

Inhibitors of cellular necrosis Download PDF

Info

Publication number
AU2004315596B2
AU2004315596B2 AU2004315596A AU2004315596A AU2004315596B2 AU 2004315596 B2 AU2004315596 B2 AU 2004315596B2 AU 2004315596 A AU2004315596 A AU 2004315596A AU 2004315596 A AU2004315596 A AU 2004315596A AU 2004315596 B2 AU2004315596 B2 AU 2004315596B2
Authority
AU
Australia
Prior art keywords
lower alkyl
substituted
aryl
heteroaryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004315596A
Other languages
English (en)
Other versions
AU2004315596A1 (en
Inventor
Gregory D. Cuny
Alexei Degterev
Prakash Jagtap
Junying Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Harvard University
Original Assignee
Brigham and Womens Hospital Inc
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Harvard University filed Critical Brigham and Womens Hospital Inc
Publication of AU2004315596A1 publication Critical patent/AU2004315596A1/en
Application granted granted Critical
Publication of AU2004315596B2 publication Critical patent/AU2004315596B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2004315596A 2003-08-29 2004-08-30 Inhibitors of cellular necrosis Ceased AU2004315596B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49888203P 2003-08-29 2003-08-29
US60/498,882 2003-08-29
PCT/US2004/028270 WO2005077344A2 (en) 2003-08-29 2004-08-30 Hydantoin derivatives as inhibitors of cellular necrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012201058A Division AU2012201058A1 (en) 2003-08-29 2012-02-23 Inhibitors of cellular necrosis

Publications (2)

Publication Number Publication Date
AU2004315596A1 AU2004315596A1 (en) 2005-08-25
AU2004315596B2 true AU2004315596B2 (en) 2011-11-24

Family

ID=34860156

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004315596A Ceased AU2004315596B2 (en) 2003-08-29 2004-08-30 Inhibitors of cellular necrosis

Country Status (11)

Country Link
US (3) US7491743B2 (enExample)
EP (3) EP1663184A2 (enExample)
JP (2) JP2007504171A (enExample)
AU (1) AU2004315596B2 (enExample)
CA (1) CA2536622C (enExample)
DK (1) DK2384753T3 (enExample)
ES (1) ES2567135T3 (enExample)
HU (1) HUE027546T2 (enExample)
PL (1) PL2384753T3 (enExample)
SI (1) SI2384753T1 (enExample)
WO (1) WO2005077344A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004093871A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel methods for the treatment of cancer
DK2384753T3 (en) * 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoin derivatives as inhibitors of cell necrosis
JP2007521835A (ja) * 2004-02-10 2007-08-09 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法
US7920101B2 (en) * 2004-10-08 2011-04-05 Sharp Laboratories Of America, Inc. Methods and systems for imaging device display standardization
US20070021421A1 (en) * 2005-07-25 2007-01-25 Hampton Thomas G Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis
US8324262B2 (en) * 2005-12-20 2012-12-04 The Brigham And Women's Hospital, Inc. Tricyclic necrostatin compounds
EP2003119A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Substituierte Acetamide als Modulatoren des EP2-Rezeptors
EP3034494A1 (en) 2007-08-15 2016-06-22 President and Fellows of Harvard College Heterocyclic inhibitors of necroptosis
US8304421B2 (en) * 2008-09-30 2012-11-06 Vanderbilt University Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
WO2010075290A1 (en) * 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
WO2010075561A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
EP2560629B1 (en) 2010-04-23 2020-06-03 Massachusetts Eye & Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US20140024598A1 (en) 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
US9643977B2 (en) 2011-03-11 2017-05-09 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
CA2888805C (en) 2011-10-21 2020-07-14 Massachusetts Eye And Ear Infirmary Methods and compositions for promoting axon regeneration and nerve function
JP2016514693A (ja) 2013-03-15 2016-05-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ハイブリッド型ネクロトーシス阻害剤
WO2014152182A1 (en) * 2013-03-15 2014-09-25 President And Fellows Of Harvard College Deuterated heterocyclic inhibitors of necroptosis
CN105394045B (zh) * 2014-09-04 2020-02-14 中国科学院上海巴斯德研究所 一种肠道病毒的小分子化合物抑制剂及其应用
TW201632516A (zh) 2014-12-11 2016-09-16 哈佛大學校長及研究員協會 細胞壞死抑制劑與相關方法
CA2972366C (en) 2014-12-24 2020-04-21 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
AU2015371824B2 (en) 2014-12-24 2019-09-19 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
ES2885474T3 (es) 2015-10-13 2021-12-13 Inst Nat Sante Rech Med Derivados de sibirilina para la utilización en la prevención y/o tratamiento de trastornos asociados a la necroptosis celular
US10457678B2 (en) 2015-10-13 2019-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis
SG11201806302RA (en) 2016-02-05 2018-08-30 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
WO2018073321A1 (en) 2016-10-18 2018-04-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
WO2018154520A1 (en) 2017-02-27 2018-08-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
WO2020018888A1 (en) 2018-07-20 2020-01-23 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
WO2020103859A1 (en) 2018-11-20 2020-05-28 Sironax Ltd RIP1 Inhibitors
US10744153B1 (en) * 2019-07-01 2020-08-18 Cloudbreak Therapeutics Llc Compositions and methods for treating meibomian gland dysfunction
US20230129364A1 (en) * 2019-12-26 2023-04-27 Yonsei University, University - Industry Foundation (UIF) Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or tau protein-associated diseases containing same
EP3875086A1 (en) * 2020-03-04 2021-09-08 Technische Universität Dresden Dual-inhibitors of cellular necroptosis and ferroptosis for use in the treatment of organ transplant patients
KR20220161394A (ko) * 2020-03-31 2022-12-06 마틴 오글트리 Covid-19의 치료를 위한 방법 및 트롬복산 a2 수용체 길항제의 약학 조성물
CA3183676A1 (en) 2020-05-20 2021-11-25 Sironax Ltd. Piperazine cyclic ureas
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use
CN112263576A (zh) * 2020-09-30 2021-01-26 浙江大学 化合物zju-37在制备肝脏疾病预防和/或治疗药物中的应用
IL314082A (en) 2022-01-12 2024-09-01 Denali Therapeutics Inc Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110536A (en) * 1977-04-18 1978-08-29 Miles Laboratories, Inc. Derivatives of 5-(indol-3-yl)hydantoin
GB2080803A (en) * 1980-07-28 1982-02-10 Pfizer Hypoglycemic 5-substituted oxazolidine-2,4-diones
WO1990004183A1 (en) * 1988-10-07 1990-04-19 Commonwealth Scientific And Industrial Research Organisation Method for preparation of thiohydantoins and for protein sequence analysis
US5593697A (en) * 1991-03-26 1997-01-14 Csl Limited Single dose vaccination system
WO2001028493A2 (en) * 1999-10-15 2001-04-26 President And Fellows Of Harvard College Small molecule inhibitors of necrosis

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
JPS5113156B2 (enExample) * 1972-10-21 1976-04-26
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4016037A (en) * 1975-10-15 1977-04-05 Ajinomoto Co., Inc. Method for producing L-amino acid
DE2728523C2 (de) * 1977-06-23 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 4-Methyl-1,2,3-thiadiazol-5-carbonsäure-(cyclohexylmethyl)-amid, Mittel mit herbizider und wachstumsregulatorischer Wirkung enthaltend diese Verbindung sowie Verfahren zu seiner Herstellung
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5810074B2 (ja) * 1979-07-18 1983-02-24 味の素株式会社 新規微生物
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4332952A (en) * 1980-07-28 1982-06-01 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US4780401A (en) 1984-04-09 1988-10-25 Ciba-Geigy Corporation Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications
EP0164247B1 (en) * 1984-06-07 1989-01-11 Pfizer Limited Dihydropyridines
JPS6122081A (ja) * 1984-07-10 1986-01-30 Mitsui Toatsu Chem Inc ヒダントイン化合物の製造法
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
DE3685626T2 (de) 1985-09-26 1993-01-28 Beckmann Research Inst Of The Sequenzierung von peptiden.
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4772684A (en) 1987-01-20 1988-09-20 Triton Biosciences, Inc. Peptides affecting blood pressure regulation
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5081127A (en) 1988-01-07 1992-01-14 E. I. Du Pont De Nemours And Company Substituted 1,2,3-triazole angiotensin II antagonists
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
IE62214B1 (en) 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
JPH0219363A (ja) * 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
EP0377083B1 (de) 1989-01-02 1993-09-22 Rütgerswerke Aktiengesellschaft Verfahren zur Herstellung von L-alpha-Aminosäuren
DE4004820A1 (de) 1989-08-05 1991-04-25 Bayer Ag Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5085992A (en) 1990-07-19 1992-02-04 Merck & Co., Inc. Microbial transformation process for antihypertensive products
JPH054910A (ja) * 1990-07-31 1993-01-14 Nikka Chem Co Ltd 化粧料組成物
WO1992004045A1 (en) 1990-08-31 1992-03-19 Warner-Lambert Company Novel cholecystokinin antagonists, their preparation and therapeutic use
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5087634A (en) 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
US5693643A (en) 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
JP2788677B2 (ja) 1994-01-10 1998-08-20 メルク フロスト カナダ インコーポレーテツド Ｃｏｘ−２阻害剤としてのフェニル複素環
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
JPH10507765A (ja) 1994-10-27 1998-07-28 メルク フロスト カナダ インコーポレーテツド シクロオキシゲナーゼ−２阻害剤として有用なスチルベン誘導体
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
AU4424496A (en) 1995-03-27 1996-10-16 Warner-Lambert Company A method for the synthesis of mixtures of compounds
US6166054A (en) * 1995-03-31 2000-12-26 Nihon Nohyaku Co., Ltd. Agricultural and horticultural disease controller and a method for controlling the diseases
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en) 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5922742A (en) 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
EP0930305B1 (en) * 1996-09-30 2003-05-14 Nihon Nohyaku Co., Ltd. 1,2,3-thiadiazole derivatives and salts thereof, disease controlling agents for agricultural and horticultural use, and method for the use thereof
AU6541898A (en) 1997-03-03 1998-09-22 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
ATE238661T1 (de) * 1998-07-30 2003-05-15 Nihon Nohyaku Co Ltd Fungizide zusammensetzung enthaltend ein 1,2,3- thiadiazolderivat sowie deren verwendung
US6756394B1 (en) * 1999-10-15 2004-06-29 President And Fellow Of Harvard College Small molecule inhibitors of necrosis
US6706766B2 (en) * 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
AU2001244596A1 (en) 2000-03-30 2001-10-15 Rei Asakai Indolylpyrrole derivatives and cell death inhibitors
GB0011071D0 (en) 2000-05-08 2000-06-28 Novartis Ag Organic compounds
JP4529338B2 (ja) * 2001-03-08 2010-08-25 味の素株式会社 ヒダントイナーゼをコードするｄｎａ、ｎ−カルバミル−ｌ−アミノ酸ハイドロラーゼをコードするｄｎａ、組み換えｄｎａ、形質転換された細胞、タンパク質の製造方法および光学活性アミノ酸の製造方法
WO2003043988A1 (en) 2001-11-22 2003-05-30 Ono Pharmaceutical Co., Ltd. Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
US6797708B2 (en) * 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
JP3659224B2 (ja) 2001-12-26 2005-06-15 村田機械株式会社 インターネットファクシミリ装置
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7320986B2 (en) * 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
DK2384753T3 (en) * 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoin derivatives as inhibitors of cell necrosis
WO2005028664A2 (en) 2003-09-17 2005-03-31 University Of Massachusetts Modulation of programmed necrosis
US6887993B1 (en) * 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
EP1720857B1 (en) * 2004-02-19 2011-07-13 Bayer Schering Pharma Aktiengesellschaft Dihydropyridinone derivatives
KR101155288B1 (ko) * 2004-07-30 2012-07-02 엑셀리시스, 인코포레이티드 의약제로서의 피롤 유도체
US7595337B2 (en) 2005-02-10 2009-09-29 Merck & Co. Inc. Mitotic kinesin inhibitors
WO2007053662A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
US8324262B2 (en) * 2005-12-20 2012-12-04 The Brigham And Women's Hospital, Inc. Tricyclic necrostatin compounds
AR056882A1 (es) 2006-02-01 2007-10-31 Bayer Cropscience Sa Derivados del fungicida n- cicloalquil- bencil- amida
WO2008006883A2 (en) 2006-07-13 2008-01-17 4Sc Ag Benzopyranopyrazoles
AU2007307044B2 (en) * 2006-10-10 2014-03-20 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
EP3034494A1 (en) * 2007-08-15 2016-06-22 President and Fellows of Harvard College Heterocyclic inhibitors of necroptosis
JP5004910B2 (ja) 2008-09-08 2012-08-22 三菱電機株式会社 屋根材型太陽電池パネル装置及びその間カバー体
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
WO2010075561A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110536A (en) * 1977-04-18 1978-08-29 Miles Laboratories, Inc. Derivatives of 5-(indol-3-yl)hydantoin
GB2080803A (en) * 1980-07-28 1982-02-10 Pfizer Hypoglycemic 5-substituted oxazolidine-2,4-diones
WO1990004183A1 (en) * 1988-10-07 1990-04-19 Commonwealth Scientific And Industrial Research Organisation Method for preparation of thiohydantoins and for protein sequence analysis
US5593697A (en) * 1991-03-26 1997-01-14 Csl Limited Single dose vaccination system
WO2001028493A2 (en) * 1999-10-15 2001-04-26 President And Fellows Of Harvard College Small molecule inhibitors of necrosis

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Brana, M. F. et al (1987) Heterocycles, 26(1):95-100 *
CAS Registry Number 109063-48-1 (11 June 1987) *
CAS Registry Number 159308-51-7 (2 December 1994) *
CAS Registry Number 160448-59-9 (27 January 1995) *
CAS Registry Number 21753-16-2 (16 November 1984) *
CAS Registry Number 428442-42-6 (11 June 2002) *
CAS Registry Number 61159-99-7 (16 November 1984) *
Horwell, D. C. et al (1998) Tetrahedron Lett. 39:8729-8732 *
Ooms, F. et al (2002) J. Med. Chem.,45(9):1748-1756 *
Toniolo, C. (1970) Tetrahedron, 26(23):5479-5488 *

Also Published As

Publication number Publication date
US8741942B2 (en) 2014-06-03
ES2567135T3 (es) 2016-04-20
US20120149702A1 (en) 2012-06-14
EP3081214A2 (en) 2016-10-19
JP5401502B2 (ja) 2014-01-29
JP2007504171A (ja) 2007-03-01
WO2005077344A2 (en) 2005-08-25
JP2011157404A (ja) 2011-08-18
US20110144169A1 (en) 2011-06-16
WO2005077344A3 (en) 2006-03-16
AU2004315596A1 (en) 2005-08-25
EP3081214A3 (en) 2016-11-16
US8143300B2 (en) 2012-03-27
EP2384753B1 (en) 2016-01-06
CA2536622C (en) 2014-02-11
EP1663184A2 (en) 2006-06-07
US7491743B2 (en) 2009-02-17
HUE027546T2 (en) 2016-10-28
SI2384753T1 (sl) 2016-06-30
DK2384753T3 (en) 2016-04-11
PL2384753T3 (pl) 2016-09-30
US20050119260A1 (en) 2005-06-02
EP2384753A1 (en) 2011-11-09
CA2536622A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
AU2004315596B2 (en) Inhibitors of cellular necrosis
US20240190837A1 (en) Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
JP5366812B2 (ja) 化合物、スクリーニング、および治療方法
JP3869721B2 (ja) Ｃｇｒｐアンタゴニストとしての新規なシクロプロパン化合物、前記化合物を含む医薬及びその製造方法
WO2013170186A1 (en) Carbazole-containing sulfonamides as cryptochrome modulators
JP2003505369A (ja) 偏頭痛を治療するための複素環式化合物
JP2002518482A (ja) β−アミロイドペプチド放出および／またはその合成を阻害する化合物
US6337342B1 (en) Bis-aryl or heteroaryl indoles
AU2012201058A1 (en) Inhibitors of cellular necrosis
HK1230091A1 (en) Inhibitors of cellular necrosis
US6492409B1 (en) Kinase inhibitors
CA2567483A1 (en) Pyrazinylmethyl lactam derivatives
HK1234740B (zh) 作为隐花色素调节剂的含有咔唑的酰胺类、氨基甲酸酯类和脲类
BR112016023446B1 (pt) Composto modulador de criptocromo (cry), composição farmacêutica que compreende o mesmo e uso da dita composição para o tratamento ou alívio de um sintoma de uma doença ou transtorno mediado por cry

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired